Lexeo Therapeutics - Ataxia UK

Lexeo Therapeutics

Lexeo Therapeutics provides updates on their gene therapy programme for Friedreich’s ataxia cardiomyopathy

Friedreich's ataxia, Friedreich's ataxia pharma news, Research News /

On March 24th 2025, the pharmaceutical company Lexeo Therapeutics provided a number of updates on their phase 1/2 trial of the gene therapy drug LX2006 for Friedreich’s ataxia (FA) cardiomyopathy.  […]

Lexeo Therapeutics provides updates on their gene therapy programme for Friedreich’s ataxia cardiomyopathy Read More »

Lexeo announces positive results from their phase 1/2 clinical trial programme for FA cardiomyopathy

1 Comment / Friedreich's ataxia, Friedreich's ataxia pharma news, Research News /

Lexeo Therapeutics is a pharmaceutical company developing a gene therapy called LX2006 for people with Friedreich’s ataxia (FA) hypertrophic cardiomyopathy (disease of the heart involving stretching, thickening, or stiffening of

Lexeo announces positive results from their phase 1/2 clinical trial programme for FA cardiomyopathy Read More »

Cart
Checkout - £0.00
  • 0
  • 1
Scroll to Top